REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/15/2026
Back to search
Official data from USPTO
ITM MEDICAL ISOTOPES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
06/16/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
07/28/2020
Registration date
06/15/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/15/2021
Last transaction
06/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
25
Owner location
DE
Examiner
BHUPATHI, TARA
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of "ITM MEDICAL ISOTOPES" in stylized form with two circles emanating from the left corner of the "I" in "ITM" at a diagonal.
Holders and representatives
Holders
I. S. (pessoa física)
ITM Isotopen Technologien München AG
Representatives
Kari Moyer-Henry Lewis Kohn & Walker LLP
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposesin particular radiopharmaceutical preparations for endo-radionuclide therapybrachytherapy and radiopharmaceutical preparations for positron emission tomography PET or single photon emission tomography SPECTtarget radionuclide and peptide receptor radionuclide therapy PRRT; theranostics in the field of precision oncology; radiopharmaceutical productslutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncologyradiopharmaceuticals containing radioisotopese.g. lutetium-177actinium-225yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target moleculee.g. peptide or antibodydepending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexesgallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin GEP-NET; radiopharmaceuticals for use in the therapy of GEP-NETosteosarcomabone metastasesprostate cancerbreast cancerbrain cancerovarian cancer; radiopharmaceuticals containing radioisotopes with short half-livessuch as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET positron emission tomography or SPECT single photon emission tomographyfor the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-livesin particular lutetium-177actinium-225 or yttrium-90 for the treatment of tumour diseases
Class 10
Medical instrumentsapparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controllingregulating and measuring apparatus as parts of medical instrumentsapparatus and containers included in this classin particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes
Class 42
Conducting clinical trials for others at all stages and in various indicationsparticularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin GEP-NET
Class 44
Medical servicesin particular services relating to radiotherapeutic and radiodiagnostic oncologycardiologyangiologyneuroradiology and nuclear medicine and brachytherapiesincluding intercavitaryinterstitial and intravascular brachytherapyradionuclide labellingPET and SPECT scanning and target radionuclide therapypeptide receptor radionuclide therapy PRRTpersonal nuclear medicine and precision oncology
Publications
History of USPTO decisions and trademark events.
36 publications found
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/26/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/15/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/21/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
09/30/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
09/30/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/15/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
06/15/2021
GPNX
NOTIFICATION PROCESSED BY IB
04/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/30/2021
PUBO
PUBLISHED FOR OPPOSITION
03/30/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/15/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/10/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/23/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
02/23/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/23/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
02/23/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/23/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/14/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/12/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/12/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/12/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/12/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/12/2021
RFNT
REFUSAL PROCESSED BY IB
12/27/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/08/2020
RFRR
REFUSAL PROCESSED BY MPU
12/08/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/20/2020
CNRT
NON-FINAL ACTION WRITTEN
11/19/2020
DOCK
ASSIGNED TO EXAMINER
11/16/2020
MAFR
APPLICATION FILING RECEIPT MAILED
10/23/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/19/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/15/2020
Continuous trademark protection
Get notified about every new filing that threatens ITM MEDICAL ISOTOPES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.